Search results :

Levetiracetam

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: N03AX14

Side effects

Options: Show MedDRA Preferred Terms,   display all 86 labels

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Accidental injury 10.3% - 17% 10% - 16.5% x x x x x
Vomiting 2.2% - 15% 2% - 13% x x x x x x x x x x x x x x
Headache 1.19% - 19% 0.57% - 15% x x x x x x x x x x x x x x x x x x x x
Nasopharyngitis common, 7% - 15% 5% - 12% x x x x x x x x x x x x x x
Infection 13% - 13.2% 7.4% - 8% x x x x x x x x x x x x x x x x x x x x
Somnolence 1.67% - 23% 0% - 11% x x x x x x x x x x x x x x x x x x x x
Aggression postmarketing, 10% 5% x x x x x x x x x
Fatigue very common, 10% - 15% 5% - 10% x x x x x x x x x x x x x x x
Asthenia 1.3% - 15% 0% - 10% x x x x x x x x x x x x x x x x x x x x
Cough 9% - 11% 5% - 7% x x x x x x x x x
Nasal congestion 9% 2% x x x x x x x x
Abdominal pain upper 9% 8% x x x x x x x x
Diarrhoea 4.2% - 8% 5% - 7% x x x x x x x x x x x x x x x x
Gastrointestinal disorder 8% 7% x x x x x x x x x x x x x
Personality disorder common, 8% 7% x x x x x x x x
Decreased appetite 8% 2% x x x x x x x x
Dizziness 1% - 9.2% 0% - 5% x x x x x x x x x x x x x x x x x x x x
Pain 6% - 7% 3% - 6.6% x x x x x x x x x x x x x x x x
Pharyngitis 5.7% - 10% 0% - 8% x x x x x x x x x x x x x x x x x x
Abnormal behaviour postmarketing, 7% 4% x x x x x x x x x
Pharyngolaryngeal pain 7% 4% x x x x x x x x
Irritability postmarketing — 1.67% - 12% 0% - 2% x x x x x x x x x x x x x x x x
Lethargy 6% 2% x x x x x x x x x
Agitation 4% - 6% 1% x x x x x x x x x x x x
Eczema common x x x x x x x x x x x x
Nausea 4.2% - 5% 3% - 4.6% x x x x x x x x x
Myalgia common x x x x x x x x x x x x
Disturbance in attention common x x x x x x x x x x x x
Memory impairment common x x x x x x x x x x x x
Vision blurred common x x x x x x x x x x x x
Balance disorder common x x x x x x x x x x x x
Influenza 3% - 8% 1% - 6% x x x x x x x x x x x x x x x x x x
Albuminuria 4% 0% x x x
Back pain 4% 4.6% x x x x x
Depression 1.67% - 5% 0% - 2.3% x x x x x x x x x x x x x x x x x x
Ecchymosis 1.5% - 4% 1% - 1.1% x x x x x x
Gastroenteritis 1.2% - 4% 0% - 2% x x x x x x x x x x x x x
Head injury 4% 0% x x x x x x x x
Nervousness 1.67% - 10% 0% - 2% x x x x x x x x x x x x x x x x x x x x
Rhinitis 2% - 13% 0% - 8% x x x x x x x x x x x x x x x x x
Abdominal pain 3.7% 5.1% x x x x x x
Anorexia 2.4% - 13% 2% - 8% x x x x x x x x x x x x x x x x x
Ataxia 2.5% - 3% 1% - 1.4% x x x x x x x x x x x x x x x x x x x x
Constipation 3% 1% x x x x x x x x x x x x x
Contusion 3% 1% x x x x x x x x
Vertigo 2.5% - 5% 1% - 3% x x x x x x x x x x x x x x x x x x
Mood swings common, 1.6% - 6% 0% - 4% x x x x x x x x x x x x x x x x x x
Coordination abnormal 3% 2% x x x x x x x x x x
Convulsion 2.38% - 6% 2.85% - 6.8% x x x x
Dyspepsia 2.8% 3.4% x x x x x x
Amblyopia 1.2% - 2% 0% - 1.4% x x x x x
Amnesia 1.6% - 2% 0.3% - 1% x x x x x x x x x x x x x x x x x x
Anxiety 1.6% - 3.33% 1% - 2% x x x x x x x x x x x x x x x x x x
Arthralgia 2% 0% x x x x x x x x x x x x x
Asthma 2% 1% x x x
Neck pain 2% - 8% 1% - 2% x x x x x x x x x x x x x x x
Confusional state postmarketing, 2% 0% x x x x x x x x x x x x x x
Conjunctivitis 2% - 3% 0% - 2% x x x x x x x x x x x
Dehydration 2% 1% x x x
Diplopia 1.67% - 2.4% 0% - 1.7% x x x x x x x x x x x x x x x x x
Ear pain 2% 0% - 1% x x x x x x x x x x x
Hostility 2% - 12% 0.6% - 6% x x x x x x x x x x x x x x x x x x x x
Paraesthesia 1.9% - 2% 1% - 1.7% x x x x x x x x x x x x x x x x x
Pruritus common, 2% 0% x x x x x x
Sinusitis 2% - 2.1% 0.9% - 1% x x x x x x x x x x x x x x x x x x x
Viral infection 2% 1% x x x
Vesiculobullous rash 2% 0% x x x
Hyperreflexia 2% 1% x x x
Skin discolouration 2% 0% x x x
Affect lability 2% 1% x x x x x x x x x
Urine abnormality 2% 1% x x x
Depressed mood 1.67% - 2% 0% x x x x x x x x x x x x
Joint sprain 2% 1% x x x x x x x x
Face oedema 2% 1% x x x
Cough increased 2% - 11% 1% - 7% x x x x x x x x x x x x x x x x
Hypersomnia 1.67% - 2% 0% x x x x x x x x x x x x
Insomnia 1.67% - 5% 0% - 3% x x x x x x x x x x x x x x x x x
Urinary tract infection 1.9% 3.4% x x x x x
Tooth disorder 1.5% 0.6% x
Tremor 1.5% 1.7% x x x x x x
Thinking abnormal 1.5% 1.4% x x x x x x x
Bronchitis 1.3% 1.4% x x x x x
Chest pain 1.3% 1.1% x x x x x
Body temperature increased 1.3% 1.7% x x x x x
Drug level increased 1.3% 0.9% x x x x x
Gingivitis 1.2% 0.6% x x x x x
Otitis media 1.2% 0.9% x x x x x
Weight increased 1.2% 1.1% x x x x x
Psychotic disorder postmarketing, 1% 0%
Agranulocytosis postmarketing x x
Alopecia postmarketing x x x x x x x x x x x x x x x x x x
Anger postmarketing x
Mental disorder postmarketing x x x x x x x x x x x x x x x x x
Dyskinesia postmarketing x x x x x x
Eosinophilia postmarketing x
Toxic epidermal necrolysis postmarketing x
Erythema multiforme postmarketing x x x x x x x x x x x
Hallucination postmarketing x
Blood disorder postmarketing x
Hepatitis postmarketing x x x x x x x x x x x x x x x x x
Hyponatraemia postmarketing x
Leukopenia postmarketing x x x x x x x x x x x x x x x x x x x
Nervous system disorder postmarketing x x x x x x x x x x x x x x x x
Neutropenia postmarketing x x x x x x x x x x x x x x x x x x x
Pancreatitis postmarketing x x x x x x x x x x x x x x x x x x
Pancytopenia postmarketing x x x x x x x x x x x x x x x x x x x
Stevens-Johnson syndrome postmarketing x
Suicide postmarketing x
Suicide attempt postmarketing x
Thrombocytopenia postmarketing, common x x x x x x x x x x x x x x x x x x x
Weight decreased postmarketing x x x x x x x x x x x x x x x x x
Choreoathetosis postmarketing x x x x x x x
Hepatic failure postmarketing x x x x x x x x x x x x x x x x
Panic attack postmarketing x x x
Liver function test abnormal postmarketing x x x x x x x x x x x x x x x x x
Muscular weakness postmarketing x x x
Malnutrition postmarketing x x x x x x x x x
Suicidal ideation postmarketing x
Drug interaction postmarketing
Completed suicide postmarketing x x x x x
Raised liver function tests postmarketing
Suicidal behaviour postmarketing x x x x x x x x x x x x
Common cold x
Connective tissue disorder x x x x x x x x x x x x x x
Depersonalisation
Drowsiness
Drug abuse
Dysmenorrhoea
Epistaxis x x x x x
Rash 0% - 2.8% 1.14% - 4% x x x x x x x x x x
Eye disorder x x x x x x x x x
Hypersensitivity x x x x x
Immune system disorder
Liver disorder
Mediastinal disorder x x x x x x x x x
Metabolic disorder
Fungal infection x x x x x
Neurosis
Pregnancy x x x x x x x x x
Skin disorder
Status epilepticus x x x x x
Toothache
Upper respiratory tract infection x
Urinary incontinence x x x x x
Apathy
Lower respiratory tract infection
Mouth ulceration x x x
Paranoid reaction
Unspecified disorder of skin and subcutaneous tissue x
Community acquired infection
Function kidney decreased
Teratogenicity
Psychiatric symptom x x x x x x
Antisocial behaviour
Withdrawal seizures x x x x x x x x x
Euphoric mood
Throat sore
Hepatobiliary disease x
Psychotic depression
Hyperkinesia x x x x x x x x x
Progesterone levels
Dependence
Gait disturbance
White blood cell count decreased
Infestation NOS x x x x x x x x x x x x x x x x
Blood and lymphatic system disorders x
Ear and labyrinth disorders x x x x x x x x x x x x x x
Procedural complication
Respiratory failure x x x
Rhinorrhoea

Indications

Information about indications was extracted from the indications and usage sections of the labels.

LEVETIRACETAM / APO-LEVETIRACETAM

Side effects:30
Source:Health Canada

LEVETIRACETAM

Side effects:45
Source:FDA Structured Product Label

LEVETIRACETAM

Side effects:46
Source:FDA Structured Product Label

LEVETIRACETAM

Side effects:48
Source:FDA Structured Product Label

LEVETIRACETAM

Side effects:51
Source:FDA Structured Product Label

LEVETIRACETAM

Side effects:51
Source:FDA Structured Product Label

LEVETIRACETAM

Side effects:58
Source:FDA Structured Product Label

LEVETIRACETAM

Side effects:59
Source:FDA Structured Product Label

LEVETIRACETAM

Side effects:77
Source:FDA Structured Product Label

LEVETIRACETAM / KEPPRA

Side effects:77
Source:FDA

levetiracetam / levetiracetam

Side effects:78
Source:EMA

LEVETIRACETAM

Side effects:81
Source:FDA Structured Product Label

LEVETIRACETAM

Side effects:81
Source:FDA Structured Product Label

LEVETIRACETAM

Side effects:81
Source:FDA Structured Product Label

LEVETIRACETAM

Side effects:83
Source:FDA Structured Product Label

LEVETIRACETAM

Side effects:83
Source:FDA Structured Product Label

LEVETIRACETAM

Side effects:84
Source:FDA Structured Product Label

levetiracetam

Side effects:88
Source:FDA Structured Product Label

LEVETIRACETAM / KEPPRA

Side effects:89
Source:FDA

levetiracetam

Side effects:91
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label